partner with kode

work with Kode Biotech

Custom FSL constructs, licensing, research collaboration and Kode Immunoeducer partnerships.

Partner with Kode: six ways to work together

Custom FSL constructs

If your molecule is not in our catalogue, talk to us, as we often make bespoke constructs.

Start an enquiry ↓ About FSL constructs →

License Kode Technology

Kode Biotech owns Kode Technology and licenses it to companies developing new products.

Discuss a licence ↓ The Kode Group →

Research collaboration

Working on cell surfaces, antibodies or glycans? Talk to us about using Kode Technology in your research.

Get in touch ↓ Science and Publications →

Human cancer KIEs

Partner with Equitable Oncology, which coordinates the clinical, scientific and philanthropic partnerships that advance K5K and AGI-134.

Equitable Oncology → About KIEs →

Veterinary cancer KIEs

Partner with Kode Veterinary Sciences on developing and commercialising Kv9.

Kode Veterinary Sciences → Kv9 →

Buy research FSLs

Catalogue FSL constructs and glycoconjugates from GlycoNZ (glyconz.com) and Merck MilliporeSigma.

glyconz.com →

Custom FSL constructs: how a project works

Tell usWhat you want to attach, and to what.
AdviseWe advise on the construct and how it will be used.
Design and makeKode Biotech designs the construct and manages its making, at research or larger scale.
SupplyYou receive the construct, with technical support.

Partner with Kode: technologies available for licence or acquisition

Kode Technology has uses beyond our own programmes. The technologies below are available to partners. The information here is non-confidential; further data are available under a confidentiality agreement.

Alpha-Gal oncolytic virus

An oncolytic virus that carries the gene for the enzyme α1,3-galactosyltransferase. Tumour cells it infects display the alpha-Gal epitope, which the body's natural anti-Gal antibodies recognise.

Stage
Patent rights. Kode Agalimmune is not developing the programme itself.
IP
Granted in the US (US 12,023,362 B2), Europe (EP 3280798 B1), Canada, Japan, Korea, India, Israel, Mexico, Russia and Hong Kong
Sought
Acquisition of the patent family
Request an info pack

Antimicrobial coatings for dressings and implants

FSL constructs coat almost any surface (metals, plastics, ceramics, polymers and nanofibres) in seconds to minutes, by dipping, spraying, painting or printing. They can hold antimicrobial agents at the surface through repeated washing.

Evidence
In a proof-of-concept study, a wound dressing given an FSL antimicrobial coating stayed sterile after challenge with about 3 million S. aureus; results were similar with S. epidermidis, P. aeruginosa and E. coli. Coatings have also been shown on PVC, nanofibres and nanomembranes.
Stage
Proof of concept
Sought
Licence by field (wound care, medical devices) or co-development
Request an info pack

Liposome modification

FSL constructs insert into liposomes during or after manufacture without changing their size, shape or membrane organisation. They add surface molecules for targeting or stability.

Evidence
A doctoral study of liposome labelling found FSL constructs "very effective at labelling liposomes", with no significant change to liposome size, morphology or stability (Campbell, PhD thesis, Auckland University of Technology, 2023). A 100 nm liposome carries about 640 FSL constructs. FSL-PEG and FSL-Zero have been used to stabilise anticancer liposomes loaded with a prodrug (Tretiakova et al., Colloids and Surfaces B, 2018). Vesicles carrying FSL constructs have been taken up by cells through lectin binding.
Stage
Research
Sought
Research collaboration or licence
Request an info pack

Partner with Kode: start an enquiry